/PRNewswire/ Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2022. Cash and investments in.
KBC Group NV boosted its holdings in shares of Nektar Therapeutics (NASDAQ:NKTR – Get Rating) by 75.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 16,233 shares of the biopharmaceutical company’s stock after buying an additional 6,979 shares during the period. KBC Group NV’s […]
Analysts forecast that Nektar Therapeutics (NASDAQ:NKTR – Get Rating) will announce $22.96 million in sales for the current quarter, according to Zacks. Six analysts have issued estimates for Nektar Therapeutics’ earnings, with estimates ranging from $21.10 million to $26.25 million. Nektar Therapeutics reported sales of $28.33 million in the same quarter last year, which would […]